BRAF and central nervous system cancer: However, in contrast to previous report with U251 (BRAF wild-type) glioma cells [30], genetic and pharmacological inhibition of Wnt signaling did not affect BRAFV600E glioma cell growth and did not sensitize RGCs to BRAFV600E inhibition.